A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer
Clinical trial NCT04691804 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04691804
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2021-03-18
- Primary completion
- 2026-12-31
- Enrollment
- 496
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.